Objective: This study addresses if deficits in cognitive, attention, and inhibitory control performance in adults with ADHD are better explained by the disorder itself or by comorbid conditions.
Method: Adult patients with ADHD (n = 352) and controls (n = 94) were evaluated in the ADHD program of a tertiary hospital. The diagnostic process for ADHD and comorbidities was based on Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) criteria. Stepwise regression analyses evaluated the effect of ADHD, demographics, and comorbidities on the scores from Wechsler Adult Intelligence Scale-Revised, Continuous Performance Test, and Stroop Color and Word Test.
Results: Patients with ADHD of both genders had worse performance on neuropsychological domains, even after adjustment for comorbidities. The presence of comorbid bipolar disorder and specific phobia are associated with more Stroop errors, whereas patients with generalized anxiety disorder present a longer execution time in Stroop.
Conclusion: Neuropsychological deficits in adults with ADHD go beyond comorbidity. Specific comorbid disorders may influence the neuropsychological functioning in adults with ADHD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1087054711434155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fluctuating Impairment and Complex Presentations: Evolving Care and Research Priorities in ADHD.
J Clin Psychiatry
December 2024
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Treatments and Treatment Predictors in Patients With Substance Use Disorders and Comorbid Attention-Deficit/Hyperactivity Disorder: First Results From the International Naturalistic Cohort Study of ADHD and SUD (INCAS).
J Clin Psychiatry
December 2024
Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
Treatment of attention-deficit/ hyperactivity disorder (ADHD) in patients with a substance use disorder (SUD) and comorbid ADHD (SUD +ADHD) may have positive effects on the outcome of both conditions, but controversy exists regarding the preferred ADHD treatment in these patients. Little is known about the treatments that are provided for these patients in routine addiction care practice and the factors that are associated with treatment provision. To describe the treatments provided in everyday clinical practice and to explore factors associated with ADHD treatment provision in patients with SUD +ADHD.
View Article and Find Full Text PDFTherapeutic Efficacy and Safety of Memantine for Children and Adults With ADHD With a Focus on Glutamate-Dopamine Regulation: A Systematic Review.
J Clin Psychiatry
December 2024
Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Pharmacotherapy plays a crucial role in treating attention-deficit/ hyperactivity disorder (ADHD). However, current medications for ADHD have limitations and potential adverse effects. Glutamate, a neurotransmitter that directly and indirectly modulates dopamine neurotransmission, is considered a new therapeutic target for ADHD.
View Article and Find Full Text PDFCorrigendum: Social cognition in adult ADHD: a systematic review.
Front Psychol
December 2024
Neuropsychological and Speech Therapy Unit, Neurocenter of Southern Switzerland, Lugano, Switzerland.
[This corrects the article DOI: 10.3389/fpsyg.2022.
View Article and Find Full Text PDFTransitioning From Pediatric to Adult Psychiatric Care for ADHD in Sweden: A Nationwide Study.
J Atten Disord
December 2024
Northern Stockholm Psychiatry, Sweden.
Objective: To evaluate care transition and medication use in young adults with ADHD in Sweden.
Method: Observational retrospective study of patients with ADHD from the Swedish National Patient Register, Prescribed Drug Register, and Cause of Death Register (2018-2020). Last contact with pediatric psychiatric care, first contact with adult psychiatric care, and medication use were described for ages 18 to 21 years, inclusive.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!